Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
#51 / 65 Total
BDN - Brandywine Realty Trust - Stock Price Chart
TickerBDN [NYSE, RUT]
CompanyBrandywine Realty Trust
CountryUSA
IndustryREIT - Office
Market Cap712.49MEPS (ttm)0.14
P/E28.91EPS this Y-
Forward P/E-EPS next Y6.19%
PEG5.78EPS past 5Y-13.78%
P/S1.40EPS next 5Y5.00%
P/B0.46EPS Q/Q-
Dividend17.71%Sales Q/Q1.48%
Insider Own2.20%Inst Own94.70%
Insider Trans0.00%Inst Trans-2.20%
Short Float7.76%EarningsJul 25/a
Analyst Recom2.86Target Price5.54
Avg Volume1.99M52W Range3.42 - 7.25
Brandywine Realty Trust engages in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. It operates through the following business segments: Philadelphia Central Business District, Pennsylvania Suburbs, Austin, Texas, Metropolitan Washington, D.C., and Other. The Philadelphia Central Business District segment includes properties located in the city of Philadelphia, Pennsylvania. The Pennsylvania Suburbs segment consists of properties in Chester, Delaware, and Montgomery counties. The Austin, Texas segment focuses on properties in the City of Austin, Texas. The Metropolitan Washington D.C. segment focuses on properties in the District of Columbia, Northern Virginia, and Southern Maryland. The Other segment offers properties located in Camden County, New Jersey and in New Castle County, Delaware. The company was founded by Gerard H. Sweeney in 1986 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SWEENEY GERARD HPresident and CEOFeb 01Option Exercise6.47109,929711,2411,737,282Feb 02 07:44 PM
WIRTH TOMExecutive Vice President & CFOFeb 01Option Exercise6.4735,307228,436322,948Feb 02 06:48 PM
DEVUONO H JEFFREYEVP & Senior Managing DirectorFeb 01Option Exercise6.4725,046162,048294,528Feb 02 06:07 PM
REDD WILLIAM DEVP & Senior Managing DirectorFeb 01Option Exercise6.4722,934148,383184,653Feb 02 06:11 PM
Johnstone GeorgeEVP, OperationsFeb 01Option Exercise6.4719,399125,512293,585Feb 02 06:13 PM
TOI - Oncology Institute Inc - Stock Price Chart
TickerTOI [NASD]
CompanyOncology Institute Inc
CountryUSA
IndustryMedical Care Facilities
Market Cap97.04MEPS (ttm)-0.84
P/E-EPS this Y-142.86%
Forward P/E-EPS next Y15.69%
PEG-EPS past 5Y-
P/S0.33EPS next 5Y-
P/B1.15EPS Q/Q-202.11%
Dividend-Sales Q/Q31.69%
Insider Own63.58%Inst Own14.47%
Insider Trans0.00%Inst Trans0.93%
Short Float0.95%EarningsAug 08/a
Analyst Recom1.00Target Price2.50
Avg Volume286.25K52W Range0.33 - 5.47
The Oncology Institute, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARASCH RICHARD ADirectorMar 17Buy0.5550,00027,495257,193Mar 21 09:01 PM
Miller Matthew PChief Operating OfficerDec 16Buy0.9573,68470,000175,325Dec 20 08:07 PM
Virnich DanielPresidentDec 07Option Exercise0.86350,000301,000623,585Dec 08 07:02 PM
Kaushal MohitDirectorNov 14Sale2.1315,99434,08325,534Nov 15 06:08 PM
Havencrest Healthcare Partners10% OwnerNov 11Sale2.33365,321851,19813,362,873Nov 15 09:30 PM
PRQR - ProQR Therapeutics N.V - Stock Price Chart
TickerPRQR [NASD]
CompanyProQR Therapeutics N.V
CountryNetherlands
IndustryBiotechnology
Market Cap95.37MEPS (ttm)-0.72
P/E-EPS this Y64.47%
Forward P/E-EPS next Y-27.78%
PEG-EPS past 5Y13.21%
P/S24.97EPS next 5Y-
P/B1.69EPS Q/Q51.58%
Dividend-Sales Q/Q20.22%
Insider Own38.12%Inst Own24.70%
Insider Trans0.00%Inst Trans-2.69%
Short Float1.81%EarningsAug 03/b
Analyst Recom1.88Target Price3.85
Avg Volume198.36K52W Range0.74 - 3.85
ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
CUE - Cue Biopharma Inc - Stock Price Chart
TickerCUE [NASD, RUT]
CompanyCue Biopharma Inc
CountryUSA
IndustryBiotechnology
Market Cap89.47MEPS (ttm)-1.27
P/E-EPS this Y13.93%
Forward P/E-EPS next Y-5.07%
PEG-EPS past 5Y7.19%
P/S49.98EPS next 5Y-
P/B1.89EPS Q/Q21.23%
Dividend-Sales Q/Q5215.38%
Insider Own6.88%Inst Own30.93%
Insider Trans0.23%Inst Trans-7.24%
Short Float5.91%EarningsAug 09/a
Analyst Recom1.00Target Price10.25
Avg Volume414.89K52W Range1.99 - 5.12
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Suri AnishPRESIDENT AND CSOAug 25Buy2.764,00011,040135,638Aug 29 04:08 PM
PASSERI DANIEL RCHIEF EXECUTIVE OFFICERAug 14Buy2.863,0008,580134,578Aug 16 04:07 PM
Kiener Peter ADirectorMar 23Option Exercise2.869,68227,6919,682Mar 27 04:05 PM
Kiener Peter ADirectorMar 23Sale3.289,32530,586357Mar 27 04:05 PM
PIII - P3 Health Partners Inc - Stock Price Chart
TickerPIII [NASD, RUT]
CompanyP3 Health Partners Inc
CountryUSA
IndustryMedical Care Facilities
Market Cap188.38MEPS (ttm)-2.84
P/E-EPS this Y90.03%
Forward P/E-EPS next Y45.14%
PEG-EPS past 5Y-
P/S0.17EPS next 5Y-
P/B-EPS Q/Q97.55%
Dividend-Sales Q/Q22.13%
Insider Own57.58%Inst Own24.51%
Insider Trans12.19%Inst Trans0.15%
Short Float8.55%EarningsAug 07/a
Analyst Recom1.40Target Price5.38
Avg Volume476.89K52W Range0.70 - 6.02
P3 Health Partners, Inc. is a population health care management company, which engages in the provision of professional support services to doctors and clinicians. The firm offers capital efficient care model, data and technology, physician leadership and community outreach tools to create enhanced patient outcomes and experiences. The company was founded by Sherif Abdou and Amir Bacchus on August 20, 2020 and is headquartered in Henderson, NV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chicago Pacific Founders UGP I10% OwnerSep 13Buy2.6590,000238,22150,025,442Sep 13 04:37 PM
Chicago Pacific Founders UGP I10% OwnerSep 12Buy2.6390,000236,52049,935,442Sep 13 04:37 PM
Chicago Pacific Founders UGP I10% OwnerSep 11Buy2.5290,000227,14250,115,442Sep 15 04:02 PM
Chicago Pacific Founders UGP I10% OwnerSep 11Buy2.3490,000210,22249,845,442Sep 13 04:37 PM
Chicago Pacific Founders UGP I10% OwnerSep 07Buy2.0690,000185,31949,755,442Sep 07 05:11 PM
RDZN - Roadzen Inc - Stock Price Chart
TickerRDZN [NASD]
CompanyRoadzen Inc
CountryUSA
IndustrySoftware - Application
Market Cap104.04MEPS (ttm)0.05
P/E76.90EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.52EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own20.00%Inst Own104.18%
Insider Trans0.00%Inst Trans1.26%
Short Float0.03%Earnings-
Analyst Recom-Target Price-
Avg Volume328.26K52W Range3.86 - 17.00
Sep-22-23 03:05PM Maxim Group LLC to Host the Virtual Tech Conference Series: Emerging Growth in A.I., on Tuesday, September 26th & Wednesday, September 27th at 8:00 A.M. ET. (GlobeNewswire) -14.00%
Aug-28-23 09:00AM Vahanna Tech Edge Acquisition I Corporation Announces Shareholder Approval of Business Combination with Roadzen, Inc. on August 25, 2023 (GlobeNewswire) +20.73%
Aug-25-23 04:30PM Vahanna Tech Edge Acquisition I Corp. Announces Additional Contribution to Trust Account to Extend Deadline to Consummate Business Combination (Business Wire)
Aug-23-23 06:00PM Vahanna Tech Edge Acquisition I Corp. Announces Anticipation of Continuation as a Business Company Incorporated under the Laws of the British Virgin Islands (Business Wire)
Aug-22-23 05:00PM Vahanna Tech Edge Acquisition I Corp. Announces Extension of Deadline to Complete Business Combination (Business Wire)
Aug-15-23 04:15PM Vahanna Tech Edge Acquisition I Corp. Announces Effectiveness of S-4 Registration Statement and August 25, 2023 Extraordinary General Meeting of Shareholders to Approve Business Combination with Roadzen, Inc. (GlobeNewswire)
Jul-25-23 04:30PM Vahanna Tech Edge Acquisition I Corp. Announces Additional Contribution to Trust Account to Extend Deadline to Consummate Business Combination (Business Wire)
Jul-21-23 04:00PM Vahanna Tech Edge Acquisition I Corp. Announces Extension of Deadline to Complete Business Combination (Business Wire)
Jul-06-23 08:00AM Roadzen, Inc. Bolsters U.S. Presence with Completion of National Automobile Club Acquisition (GlobeNewswire)
Jun-23-23 04:00PM Vahanna Tech Edge Acquisition I Corp. Announces Additional Contribution to Trust Account to Extend Deadline to Consummate Business Combination (Business Wire)
Roadzen, Inc. operates as an insurance technology company. It offers auto insurance services through artificial intelligence technology. The company was founded by Rohan Malhotra on May 7, 2015 and is headquartered in Burlingame, CA.
COSM - Cosmos Health Inc - Stock Price Chart
TickerCOSM [NASD]
CompanyCosmos Health Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap17.60MEPS (ttm)-5.88
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-22.04%
P/S0.36EPS next 5Y-
P/B0.34EPS Q/Q99.61%
Dividend-Sales Q/Q-6.40%
Insider Own12.88%Inst Own5.62%
Insider Trans13.26%Inst Trans-98.13%
Short Float15.57%Earnings-
Analyst Recom-Target Price-
Avg Volume1.64M52W Range0.99 - 23.84
Sep-27-23 10:30AM Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company (ACCESSWIRE) -13.16%
Sep-26-23 11:00AM Cosmos Health Announces Expansion of Its C-Sept Brand with the Launch of C-Scrub Wash; Capitalizing on $29 Billion Global Antiseptic and Disinfectant Market (ACCESSWIRE) +9.83%
Sep-22-23 12:50PM Cosmos Health Announces Relaunch of bio-bebe, its Proprietary Organic Infant Care & Nutrition Brand; Aims to Penetrate $103bn Global Baby Food Market (ACCESSWIRE)
Sep-20-23 11:50AM Cosmos Health Announces Strategic Collaboration with C.A.PAPAELLINAS Group (ACCESSWIRE)
Sep-13-23 08:30AM Cosmos Health Starts Stock Buyback Program (ACCESSWIRE)
08:00AM BestGrowthStocks.com issues New Growth Report on Cosmos Health (News Direct)
Sep-12-23 08:30AM Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023 (ACCESSWIRE) +34.34%
Aug-15-23 07:00AM Cosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04 (ACCESSWIRE)
Aug-08-23 09:20AM Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor (ACCESSWIRE)
Aug-02-23 01:15PM Cosmos Health Continues to Expand Mediterranation Brand, Welcomes Eleonas and Olympus Mons; Boosts Exports and Secures Purchase Orders, Including from Leading Multinational Health Food Chain (ACCESSWIRE) -14.97%
Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Siokas GrigoriosChief Executive OfficerJul 20Buy2.48181,451449,9981,327,885Jul 24 11:44 AM
Siokas GrigoriosChief Executive OfficerJun 06Buy23.924,474107,0181,146,434Jun 07 01:27 PM
Siokas GrigoriosChief Executive OfficerApr 27Buy24.644,474110,2391,141,960Apr 28 09:27 AM
Siokas GrigoriosChief Executive OfficerApr 21Buy24.494,474109,5681,137,486Apr 21 02:08 PM
Siokas GrigoriosChief Executive OfficerApr 07Buy24.372,23854,5401,133,012Apr 10 01:02 PM
BHVN - Biohaven Ltd - Stock Price Chart
TickerBHVN [NYSE, RUT]
CompanyBiohaven Ltd
CountryUSA
IndustryBiotechnology
Market Cap1.56BEPS (ttm)-6.32
P/E-EPS this Y60.74%
Forward P/E-EPS next Y2.95%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.03EPS Q/Q7.01%
Dividend-Sales Q/Q-
Insider Own14.85%Inst Own90.15%
Insider Trans1.50%Inst Trans-
Short Float8.96%EarningsJul 31/b
Analyst Recom1.00Target Price26.67
Avg Volume1.00M52W Range5.54 - 27.40
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHILDS JOHN WDirectorAug 30Buy18.4450,000922,1801,975,118Aug 31 08:56 AM
CHILDS JOHN WDirectorAug 04Buy19.78100,0001,978,4301,925,118Aug 07 07:29 AM
Coric VladChief Executive OfficerOct 31Buy15.9725,800411,9951,543,394Nov 01 07:34 AM
Coric VladChief Executive OfficerOct 28Buy14.82100,0001,482,420109,565Oct 31 07:52 AM
Coric VladChief Executive OfficerOct 28Buy14.8741,930623,3521,517,594Oct 31 07:52 AM
GTHX - G1 Therapeutics Inc - Stock Price Chart
TickerGTHX [NASD]
CompanyG1 Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap66.76MEPS (ttm)-1.71
P/E-EPS this Y68.54%
Forward P/E-EPS next Y15.60%
PEG-EPS past 5Y-10.99%
P/S0.75EPS next 5Y-
P/B1.16EPS Q/Q-
Dividend-Sales Q/Q300.95%
Insider Own17.09%Inst Own30.43%
Insider Trans-0.74%Inst Trans13.36%
Short Float6.75%EarningsAug 02/b
Analyst Recom1.38Target Price30.00
Avg Volume824.86K52W Range1.17 - 13.85
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Velleca Mark A.DirectorAug 08Option Exercise0.3960,00023,156173,286Aug 10 04:11 PM
Velleca Mark A.DirectorAug 08Sale2.0060,000119,974116,000Aug 10 04:11 PM
Bailey John E. (Jack) Jr.President and CEOJul 05Sale2.452,7196,672433,563Jul 07 04:07 PM
MURDOCK TERRY LChief Operating OfficerJul 05Sale2.451,3613,33970,078Jul 07 04:08 PM
Malik RajeshChief Medical OfficerJul 05Sale2.451,3613,339136,378Jul 07 04:08 PM
RIGL - Rigel Pharmaceuticals - Stock Price Chart
TickerRIGL [NASD, RUT]
CompanyRigel Pharmaceuticals
CountryUSA
IndustryBiotechnology
Market Cap170.35MEPS (ttm)-0.22
P/E-EPS this Y27.78%
Forward P/E-EPS next Y40.97%
PEG-EPS past 5Y11.34%
P/S1.35EPS next 5Y-
P/B-EPS Q/Q51.53%
Dividend-Sales Q/Q-9.84%
Insider Own1.53%Inst Own64.35%
Insider Trans0.00%Inst Trans-8.55%
Short Float2.09%EarningsAug 01/a
Analyst Recom2.33Target Price4.16
Avg Volume1.05M52W Range0.67 - 2.04
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RODRIGUEZ RAUL RCEO, PresidentFeb 06Sale1.7520,34035,5951,680,713Feb 07 04:30 PM
Dummer WolfgangEVP & CMOFeb 02Sale1.665,3898,94672,459Feb 06 05:40 PM
Schorno Dean LEVP & Chief Financial OfficerFeb 02Sale1.665,3898,946196,519Feb 06 05:40 PM
Santos David AEVP, Chief Commercial OfficerFeb 02Sale1.665,3888,945144,612Feb 06 05:41 PM
1234567